MedtronicWith 3 quarters of operations under its belt since the $50 billion acquisition of Covidien, Medtronic (NYSE:MDT) is evaluating whether to sell off some of the Covidien assets, CEO Omar Ishrak told analysts yesterday during a conference call.
Ishrak said Covidien, which Medtronic calls its minimally invasive therapies group, has “a very clear and compelling vision for the future, which is outcomes-based and very aligned with the Medtronic mission.”
The company will take the next 6 months or so to decide if there are any ex-Covidien assets it wants to divest, he said.
